NCT02651675: A trial that was reported late by Regenxbio Inc.
This trial has reported, although it was 486 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02651675 |
|---|---|
| Title | AAV8-mediated Low Density Lipoprotein Receptor (LDLR) Gene Replacement in Subjects With Homozygous Familial Hypercholesterolemia (HoFH) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | March 31, 2016 |
| Completion date | Nov. 27, 2020 |
| Required reporting date | Nov. 27, 2021, midnight |
| Actual reporting date | March 28, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 486 |